SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals announced that the Phase 3 TRANSCEND trial…

Rhythm Pharmaceuticals, Inc. · PRESS-RELEASE filed Jul 8, 2026 at 17:07 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jul 8, 2026 at 17:07 ET

Rhythm Pharmaceuticals announced that the Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE) in acquired hypothalamic obesity were published in The New England Journal of Medicine. The data show a -19.8% placebo-adjusted BMI reduction with 80% of patients achieving ≥5% BMI reduction at 52 weeks. The publication reinforces the drug's efficacy after FDA approval (March 2026) and EMA recommendation, potentially supporting commercial adoption in a rare disease with no prior approved therapy.

  • Placebo-adjusted BMI reduction of -19.8% (p<0.0001) in Phase 3 TRANSCEND trial
  • 80% of setmelanotide-treated patients achieved ≥5% BMI reduction at 52 weeks
  • Setmelanotide was generally well tolerated with no new safety signals
  • FDA approval for acquired hypothalamic obesity obtained in March 2026; EMA CHMP recommended approval in March 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access